Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

The planned trial still needs regulatory and ethics steps, while the reported tumor and survival results come from animal models.

Rhea-AI Summary

Propanc Biopharma (PPCB) reported a narrower annual loss and outlined plans for a Phase 1b study of PRP. The study is planned to start in the first quarter of 2027, with a first patient visit scheduled for April. It would enroll up to 50 patients with advanced solid tumors in Australia. In animal models of pancreatic cancer, PRP produced greater than 90% mean tumor growth inhibition versus controls and extended median survival by more than 2.5-fold.

For the year ended June 30, 2026, net loss narrowed to $18,862,710 from $58,923,300; revenue remained at zero. Annual gross proceeds raised totaled $7.5 million, including a public offering of 1,000,000 shares at $4.00 each. Cash stood at $832,006 at June 30, and a further $2.0 million was received from the Series C facility afterward. Total liabilities fell to $3,378,251 from $5,725,616. Propanc also authorized up to $5.0 million in share repurchases and completed a $500,000 first tranche.

14 points · 3 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointNet loss narrowed to $18,862,710 from $58,923,300 for the year ended June 30, 2026, but remained a loss.
• Major pointAnnual gross proceeds raised totaled $7.5 million in the 2025–26 financial year. 2.2× market cap
• Major pointSeries C funding brought in a further $2.0 million after June 30, 2026. 59% of market cap
• Moderate pointCash rose to $832,006 at June 30, 2026, from $12,088 a year earlier.
• Moderate pointTotal liabilities fell to $3,378,251 from $5,725,616 at June 30, 2025.
• Moderate point. Forward-looking: it has not happened yet and may not happen.PRP Phase 1b study is planned to start in the first quarter of 2027, with up to 50 patients.
• Moderate pointShare repurchases totaled $500,000 in the first tranche of a program authorizing up to $5.0 million. 15% of market cap

7 minor points

• Minor pointLoss per share narrowed to $17.62 from $371.22 for the year ended June 30, 2026.
• Minor pointConvertible notes fell to zero at June 30, 2026, from $537,921 a year earlier.
• Minor pointOperating expenses fell to $18,185,569 from $57,278,131 year over year.
• Minor pointPRP animal-model results showed greater than 90% mean tumor growth inhibition versus controls.
• Minor pointMedian survival was more than 2.5-fold longer in PRP-treated animals than controls.
• Minor pointFinished-product manufacturing is underway, and raw drug substance supply for the PRP formulation is secured.
• Minor point. Forward-looking: it has not happened yet and may not happen.FyoniBio service agreement covers development and validation of an assay for the planned PRP study.

Negative

• Major point1,000,000 common shares issued at $4.00 each in the public offering dilute existing holders.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Series C convertible preferred stock issued under the private placement can dilute common holders.
• Moderate pointTotal assets fell to $12,779,912 at June 30, 2026, from $19,631,808 a year earlier.
• Moderate pointResearch and development expenses rose to $625,477 from $223,721 year over year.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Clinical trial authorization approval is still targeted for February 2027, ahead of the scheduled first patient visit.

3 minor points

• Minor pointRevenue remained at zero for the year ended June 30, 2026.
• Minor pointDeemed dividend of $932,246 increased the 2026 net loss available to common stockholders.
• Minor pointAvance memorandum records the parties' intent to collaborate on clinical delivery, rather than a completed commitment.

News Explained

The facility's $100 million ceiling is not all cash received: Propanc reports $1 million initially, $3 million by June 30, and $2 million afterward.

Propanc places the planned PRP Phase 1b study in preparation, not patient testing: finished-drug manufacture is underway, PK method validation has commenced, and HREC submission materials are being prepared.

The company reports a private-placement agreement for up to $100 million, with $1 million received initially, a further $3 million by June 30, 2026, and $2 million after that date; the ceiling is not all cash received.

A private placement is a securities sale to selected investors outside a public offering; the release identifies Series C convertible preferred shares but gives no conversion mechanics, so any resulting effect on common ownership is not established here.

The timeline places CTA submission in November 2026, review during January–February 2027, approval in February 2027, and first patient/first visit in April 2027.

At June 30, 2026, reported cash of $832,006 equaled 47.3 days of the latest reported quarterly operating cash use at that rate, a backward-looking comparison rather than a forecast.

Sources and calculations

• Propanc Biopharma corporate update and year-end financial results (2026-09-29)
• Private placement / PIPE definition (undated)
• Propanc Biopharma quarterly fundamentals (2026Q4)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate $832,006 / ($1,601,982 / 91) = 47.3 days

Argus 15 min delay 6 alerts

-2.10% vs previous close $0.52 last price 0.7x rel. volume Open Argus

Details

Market Reaction – PPCB

$0.50 – $0.56 Day Range

$3.31M Market Cap

On Sep 29, the day this news came out, the latest delayed price for PPCB is 2.10% below the previous close. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $0.52.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The Sep. 25 10-K had already reported PPCB's June-year-end results; this update covers the same annu...

Analysis

The Sep. 25 10-K had already reported PPCB's June-year-end results; this update covers the same annual reporting period, so the filing adds relevant disclosure context.

Key Figures

Gross proceeds raised: $7.5 million Private placement agreement: Up to $100 million Net loss: $18,862,710 +5 more

Gross proceeds raised

$7.5 million

2025-26 financial year

Private placement agreement

Up to $100 million

Agreement entered into to support clinical development

Net loss

$18,862,710

Year ended June 30, 2026

Quarter-end cash

$832,006

June 30, 2026

Planned study enrollment

Up to 50 patients

Phase 1b first-in-human study in advanced solid tumors

Mean tumor growth inhibition

Greater than 90%

PRP in advanced PDAC models versus vehicle controls

P-value

p < 0.001

Tumor growth inhibition in advanced PDAC models

Median overall survival extension

More than 2.5-fold

Treated animals compared with controls

Historical Context

2 past events · Latest: Sep 22

2 events

1. Sep 22

   Preclinical data

   24h Move

   +3.4%

   Reported >90% tumor-growth inhibition and >2.5-fold median survival extension in PRP models.

2. Aug 27

   Preclinical data

   24h Move

   +109.3%

   Reported >90% tumor-growth inhibition and >2.5-fold median survival extension in PRP models.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pharmacokinetics, pharmacodynamics, gmp, hrec, +1 more

5 terms

pharmacokinetics medical

"evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD)"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

pharmacodynamics medical

"pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity"

Pharmacodynamics is how a drug actually affects the body — the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.

gmp technical

"GMP manufacture of finished drug product is underway"

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

hrec regulatory

"Human Research Ethics Committee (HREC) submission is in preparation"

A Human Research Ethics Committee (HREC) is an independent review board that evaluates whether medical or social research involving people is safe, ethical and respects participants’ rights. For investors, HREC approval is a critical regulatory checkpoint—like a safety inspection for a new product—because it must be secured before clinical studies can proceed, and delays or refusals can affect a project’s timeline, costs and ultimate commercial value.

lc-ms technical

"a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay"

LC-MS is a laboratory method that first separates a mixture into its individual chemical components using liquid flow, then measures each component’s weight to identify and quantify it. For investors, LC-MS acts like a high-precision barcode scanner for molecules: it provides hard evidence about a product’s composition, purity and contaminants, which affects regulatory approvals, product quality, manufacturing risk and potential liability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027

MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported year-end financial results as of June 30, 2026 (Year end June 30).

CORPORATE HIGHLIGHTS

To commence a world-first Phase 1b FIH study of PRP in Q1, 2027

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across Australia. The two-part design, dose escalation (Part A) followed by dose expansion (Part B), is intended to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of PRP.

Several workstreams are advancing in parallel to support study start:

• Manufacturing: GMP manufacture of finished drug product is underway. A small-scale technology transfer run has been completed. Two scale-up runs are scheduled this month, with an engineering run planned for late October. Raw drug substance supply for the PRP formulation is secured after recent audit and vendor qualification processes were successfully completed.
• Bio-analytics: PK method validation has commenced. Development of an anti-drug antibody assay is underway, and in-use stability testing of the finished PRP formulation is scheduled.
• Regulatory and ethics: Supporting documentation for Human Research Ethics Committee (HREC) submission is in preparation, including the Investigator’s Brochure (IB), a briefing document drawn from the IB, and the clinical trial protocol. Documents will be provided to investigators at Australian trial sites for feasibility assessment ahead of the planned HREC submission in November 2026.
  

PRP will be administered as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle. Treatment may continue until a withdrawal criterion is met.

Compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC)

In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, three-times-weekly intravenous PRP achieved:

• Greater than 90%, mean, tumor growth inhibition versus vehicle controls (p < 0.001).
• Marked reduction in metastatic burden in the liver and peritoneum.
• Significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition (EMT) markers.
• Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, supporting lower chemotherapy doses with improved efficacy.
• Median overall survival extension of more than 2.5-fold in treated animals compared with controls.
  

Results were built on previously reported >85% tumor growth inhibition data and peer-reviewed findings on PRP’s effects on PDAC fibroblasts. Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients with a favorable safety profile and no severe treatment-related adverse events.

Memorandum of Understanding (MOU) with Avance Clinical Pty Ltd

The MOU sets out the shared intent of Propanc and Avance to work together to support the clinical delivery of Propanc’s Phase 1b, FIH clinical study for PRP. Importantly, both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving with the goal of advancing PRP efficiently from FIH into Proof-of-Concept and, as data supports, later-phase development. Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across North America, Asia Pacific, New Zealand and Europe. With more than 30 years of experience leading early phase clinical trials, they leverage the unique advantages of the Australian market, including rapid ethics approval, and up to 43.5% off with the Australian R&D tax rebate, to provide biotech companies with an accelerated pathway to clinical success.

Contract and Development Manufacturing Organization (CDMO) for GMP manufacture of PRP

The Spanish based CDMO provides end-to-end services for preclinical and clinical projects, with extensive experience in biologics production (plasmid DNA and recombinant proteins) providing services of cell line generation, banking and characterization, analytical development, process development and batches production of both drug substances and drug products. Management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study.

Service Agreement with FyoniBio GmbH to Establish & Validate Pharmacokinetics Assay for Phase 1b FIH Study

Management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development Organization (CDO) based in Berlin for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify the Company’s lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b FIH study.

Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén & Granada, Spain

A multi-year Joint Research Collaboration Agreement has been established with the Universities of Jaén (UJA) and Granada (UGR), Spain. The collaboration involves the evaluation of a senescence-modulating (i.e., anti-aging) compound to mitigate senescence and to complete experiments to further support the claims of recently filed fibrosis and cancer related patent applications, requested by Propanc to UJA’s research group “Biological Technologies of The University of Jaén” and UGR’s Research Group, “Advanced Therapies: Differentiation, Regeneration and Cancer.”

FINANCIAL HIGHLIGHTS

Proceeds raised

In the 2025-26 financial year totaled $7.5 million, gross proceeds.

Closed an underwritten public offering

1,000,000 shares at $4.00 per share, raising gross proceeds of $4.0 million. Propanc’s common stock began trading on the Nasdaq Capital Market on August 15.

Entered into a private placement agreement for up to $100 million to accelerate clinical development

Received an initial $1,000,000 investment upon issuance of 100 shares of Series C, Convertible Preferred Stock. As of June 30, a further $3,000,000 investment was received upon exercise of 100 shares of Series C, Convertible Preferred Stock.

Commenced a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock

The Company completed the first tranche of $500,000 within the first 30 days since of commencing its share repurchase program.

Year-end Financial Summary (Quarter Ended June 30, 2026)

• Total assets: $12.78 million
• Total liabilities reduced by $2.20 million
• Convertible notes reduced to $0 (from $538,000)
• Net cash from financing activities: $6.46 million
• Quarter-end cash: $832,006
• A further $2.0 million from the Series C facility received (post June 30)

The Company expects the financing facility to continually support planned R&D activities, including advancement of PRP and Rec-PRP.

Management Commentary

“The Propanc Executive team are delighted with advancements made in the past financial year,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “The Company is poised to capitalize on the foundation set in the next financial year with the advancement of PRP to a Phase 1b FIH study in up to 50 advanced cancer patients with solid tumors such as pancreatic, ovarian and refractory prostate cancers. Recent clinical advancements observed by companies such as Revolution Medicines and Erasca through KRAS inhibitors for pancreatic cancer are groundbreaking and tremendously exciting, but there is more work to be done to eliminate recurrence and metastasis in patients suffering from this killer disease. PRP is a potential breakthrough therapy that modulates the tumor micro-environment by targeting the EMT (epithelial-mesenchymal transition) process, which drives metastasis, invasion and recurrence from CSCs (cancer stem cells) which often lie dormant, post treatment, causing the cancer to return and spread. By eliminating this threat, not only can PRP improve survival, but is also non-toxic to healthy cells, meaning that patients could have a better quality of life, as well as enhance more durable response rates in combination with other treatments such as chemotherapy, checkpoint inhibitors, or KRAS inhibitors. We look forward to executing our scientific and clinical research activities in the 2026-2027 financial year.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780
info@propanc.com

Investor Contact:

irteam@propanc.com

Clinical Research Activity for PRP		Timeline
CTA		April 2025 – September 2026
Phase Ib Clinical Study Protocol
Investigator’s Brochure
CTA Compilation		October 2026 – November 2026
CTA Submission		November 2026
CTA Approval		February 2027
CTA Review		January 2027 – February 2027
Contract Research Organization and Contracts		February 2027 – March 2027
Analytical Laboratory Selection and Contracts
Trial Site Selection and Contracts
Preparation of Logistics		February 2027 – March 2027
Trial Site Initiation Visits
First Patient/First Visit		April 2027

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
		June 30, 2026				June 30, 2025
ASSETS
CURRENT ASSETS:
Cash		$	832,006			$	12,088
GST tax receivable			13,694				5,302
Prepaid expenses - current portion			7,661,967				8,334,046
Other current assets			34,923				1,380
TOTAL CURRENT ASSETS			8,542,590				8,352,816
Deferred offering costs			-				291,773
Prepaid expenses - long-term portion			4,190,543				10,925,835
Security deposit - related party			2,074				1,971
Operating lease right-of-use assets, net - related party			40,790				59,413
Property and equipment, net			3,915				-
TOTAL ASSETS		$	12,779,912			$	19,631,808
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable		$	1,131,429			$	1,249,596
Accrued expenses and other payables			855,350				1,486,550
Accrued interest			128,318				190,795
Loans payable			-				65,280
Loans payable - related parties, net of discount			460,809				415,329
Notes payable, net of discount			-				543,312
Convertible notes, net of discounts and including put premiums			-				537,921
Operating lease liability - related party, current portion			24,489				17,664
Embedded conversion option liabilities			-				403,892
Employee benefit liability			754,038				667,901
TOTAL CURRENT LIABILITIES			3,354,433				5,578,240
NON-CURRENT LIABILITIES:
Loan payable - long-term - related party, net of discount			-				105,627
Operating lease liability - long-term portion - related party			23,818				41,749
TOTAL NON-CURRENT LIABILITIES			23,818				147,376
TOTAL LIABILITIES		$	3,378,251			$	5,725,616
Commitments and Contingencies (See Note 9)
STOCKHOLDERS’ EQUITY:
Preferred stock, 1,500,005 shares authorized, $0.01 par value:
Series A preferred stock, $0.01 par value; 500,000 shares previously authorized; 0 shares issued and outstanding as of June 30, 2026 and 2025		$	-			$	-
Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of June 30, 2026 and 2025			-				-
Series C preferred stock, $0.01 par value, $10,000 stated value; 5 shares authorized; 9,900 shares designated and authorized, 200 (liquidation value of $2,000,000) shares and none issued and outstanding at June 30, 2026 and 2025, respectively			2				-
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 3,310,827 and 464,471 shares issued and outstanding as of June 30, 2026 and 2025, respectively			3,310				464
Common stock issuable (487,939 and 310 shares as of June 30, 2026 and 2025, respectively)			487				-
Additional paid-in capital			152,752,314				138,254,808
Accumulated other comprehensive income			1,176,255				1,318,917
Accumulated deficit			(144,484,230	)			(125,621,520	)
Treasury stock ($0.001 share)			(46,477	)			(46,477	)
TOTAL STOCKHOLDERS’ EQUITY			9,401,661				13,906,192
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	12,779,912			$	19,631,808

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
		For the years ended June 30,
		2026				2025
REVENUE
Revenue		$	-			$	-
OPERATING EXPENSES
Administration expenses			670,607				108,950
Compensation and related taxes			2,275,937				23,296,390
Professional and consulting expenses			14,572,616				33,622,510
Occupancy expenses - related party			40,932				26,560
Research and development			625,477				223,721
TOTAL OPERATING EXPENSES			18,185,569				57,278,131
LOSS FROM OPERATIONS			(18,185,569	)			(57,278,131	)
OTHER INCOME (EXPENSE)
Interest expense			(430,539	)			(563,757	)
Interest income			161				9
Derivative expense			-				(333,596	)
Change in fair value of derivative liabilities			13,709				212,450
Change in fair value of warrant liability			(99,695	)			-
Other expense			(6,000	)			-
Settlement expense			(320,000	)			-
Gain (loss) on extinguishment of debt, net			133,071				(871,032	)
Foreign currency transaction gain (loss)			32,152				(89,243	)
TOTAL OTHER INCOME (EXPENSE), NET			(677,141	)			(1,645,169	)
LOSS BEFORE TAXES			(18,862,710	)			(58,923,300	)
Tax benefit			-				-
NET LOSS		$	(18,862,710	)		$	(58,923,300	)
Deemed Dividend			(932,246	)			-
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS		$	(19,794,956	)		$	(58,923,300	)
BASIC AND DILUTED NET LOSS PER SHARE		$	(17.62	)		$	(371.22	)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING			1,123,709				158,727
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS		$	(19,794,956	)		$	(58,923,300	)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)			(142,662	)			49,336
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)			(142,662	)			49,336
TOTAL COMPREHENSIVE LOSS		$	(19,937,618	)		$	(58,873,964	)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Propanc Biopharma's financial results for the year ended June 30, 2026?

Propanc recorded a $18,862,710 net loss, compared with $58,923,300 a year earlier, and reported no revenue in either year. Basic and diluted loss per share was $17.62, compared with $371.22.

When is Propanc Biopharma's PRP Phase 1b trial expected to begin?

Propanc plans to start the study in the first quarter of 2027, while its trial schedule places the first patient visit in April 2027. The proposed Australian study would enroll up to 50 patients with advanced solid tumors.

What approvals remain before Propanc Biopharma's PRP trial can enroll its first patient?

Human Research Ethics Committee submission documents are being prepared for a planned November 2026 submission. Propanc's schedule also targets clinical trial authorization submission in November 2026 and approval in February 2027, before the first patient visit scheduled for April.